Business Context and Reporting Period
This Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on July 13, 2020. The report details the appointment of Jerome B. Zeldis, M.D., Ph.D., as Chief Medical Officer of the Company's majority-owned subsidiary, ViralClear Pharmaceuticals, Inc. Dr. Zeldis is also a member of the Company's board of directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the new executive appointment and associated compensation package:
- Role: Chief Medical Officer of ViralClear Pharmaceuticals, Inc.
- Base Salary: $12,500 semi-monthly.
- Annual Bonus: Eligible for up to 50% of base salary, prorated for partial years.
- Equity Grant: 50,000 restricted stock units (RSUs) awarded on July 14, 2020.
- Vesting Schedule: 16,666 RSUs vest on July 14, 2021; the remaining 33,334 RSUs vest in equal quarterly installments over the subsequent seven quarters, concluding on the third anniversary of the grant date.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The equity award is subject to the terms of the BioSig Technologies, Inc. 2012 Equity Incentive Plan and the Restricted Stock Unit Award Agreement.
Investor Verification Checklist
- Verify the exact vesting schedule and conditions for the 50,000 RSUs granted to Dr. Zeldis.
- Confirm the total annualized cash compensation cost ($300,000 base + potential $150,000 bonus).
- Review the BioSig Technologies, Inc. 2012 Equity Incentive Plan for specific forfeiture or acceleration clauses.
- Note the discrepancy between the request metadata company name ("Streamex Corp.") and the actual filing registrant ("BioSig Technologies, Inc.").